health pharma news today obesity drugs glp-1 today october 2025 Outlook for obesity in 2025: more Pharma Giants Bet on Next-Generation
Description
A GLP-1 Receptor Agonist Inhibits Aldosterone Release in Healthy Volunteers
Trials are also now being planned or conducted on cocaine-use disorder and opioids
Wang W, Nevrez L, Filippova E, Song KH, Tao B, Gu L, Wang F, Li P, Yang J
Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, Stolarski C, Shen YT, Shannon RP
In the STEP 1 and STEP 3 trials, participants with a mean BMI of 38 showed around 15% weight loss after 68 weeks treatment with 2.4mg semaglutide
Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity
